newsfilter
← Latest News
Business Wire·

Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst)